The OT-I mouse T-cell receptor (TCR) is thought to perfectly discriminate between lower-affinity self- and higher-affinity ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

T-cell therapy represents a groundbreaking advancement in cancer treatment, particularly for hematological malignancies. Despite its potential to offer curative outcomes, the field faces significant ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the immune system, and immune cells produce a potentially lifesaving antibody ...